VIVA-University Children's Cancer Centre, Khoo-Teck Puat-National University Children's Medical Institute, National University Hospital, Singapore, Singapore.
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Blood. 2022 Jul 14;140(2):156-160. doi: 10.1182/blood.2022016166.
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.
接受针对复发/难治性淋巴瘤的 CD19 CAR T 细胞治疗的患者会经历长期且严重的 B 细胞发育不全和低丙种球蛋白血症，使他们面临更严重 COVID-19 的风险。此外，Oh 等人和 Atanackovic 等人表明，尽管对基于 mRNA 的疫苗的体液反应减弱，但患者表现出正常或增强的 T 细胞功能反应，包括针对 SARS-CoV-2 变体（包括奥密克戎）的抗病毒 T 细胞活性。总的来说，这些数据强调了在接受 CD19 CAR T 细胞治疗后接种 COVID-19 疫苗的重要性，尽管存在长期的 B 细胞发育不全。
